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Oral Presentations S179of immunotherapy treatment. B7-H1 antibody administration
significantly improved long-term survival after immunotherapy
(40% vs 0% for controls), indicating that the B7-H1/PD-1
pathway inhibits development of myeloma-specific immunity. We
are addressing that possibility that other immune suppressive
mechanisms can be targeted to further improve immunotherapy
efficacy, and several candidates have been identified including
CD41Foxp31 regulatory T cells. These results support the use of
B7-H1/PD-1 blocking strategies to increase tumor immunity in
myeloma patients.70
BINARY CONTROL OF TUMOR-SPECIFIC CYTOTOXIC T LYMPHOCYTES BY
TRANSGENIC IL7 AND IL7 RECEPTOR EXPRESSION
Vera, J.F., Sanchez, C.L.,Muralidharan, S., Heslop, H.E., Rooney, C.M.,
Dotti, G., Brenner, M.K. Center for Cell and Gene Therapy CAGT,
Houston, TX
While adoptive transfer of cytotoxic T lymphocytes (CTLs) en-
grafted with chimeric antigen receptors (CARs) has produced objec-
tive clinical responses in vivo, the infused cells usually fail to persist
long-term, limiting benefit. We have recently demonstrated that
CTL persistence can be improved by engineering cells to express
the IL7 receptor alpha chain (IL7Ra) which is physiologically absent
on CTLs, followed by infusion of IL7 cytokine. However, this ap-
proach requires access to clinical grade cytokine, and biodistribution
of cytokine at tumor sites may be insufficient. To circumvent these
problems we have prepared two CTL products; one expressing a tu-
mor-specific CAR in combination with IL7Ra (product #1), and
a second engineered to co-express the same CAR and produce IL7
cytokine (product #2). In this way both products have anti-tumor ac-
tivity, mediated through the CAR, while cytokine produced from
CTL#2 should support the survival and persistence of CTL#1 ex-
pressing the IL7Ra. A binary system such as this should be intrinsi-
cally safer than incorporating a positive feedback loop of both
cytokine and receptor in a single cell.
As proof of principal we used the SFG-CAR that targets the kappa
light chain, expressed on B cell malignancies. We made two retrovi-
ral vectors, SFG-CAR/IL7Ra-GFP (#1) and SFG-CAR/IL7cyto-
mOrange (#2) and transduced EBV-CTL from 3 donors with each
vector. FACS analysis indicated that all the transgenes were ex-
pressed at approx. equivalent levels; CTL#1 (CAR, IL7Ra andPatient
Days Required
for Collection
Days to
Collection
CD34+ Stem Cells
(million/kg) in
1 1 18 21.2
2 1 18 47.4
3 1 19 22
4 1 18 17.9
5 4 19 40.6
6 1 18 19.9
7 3 19 294.2
8 2 17 13.8
9 5 18 9.25
10 2 17 21.4
11 1 24 50.0
12 2 19 66.12
13 1 18 30.4
14 2 16 43.6
15 1 19 51.0
16 1 17 15.56
17 1 17 6.8
18 1 17 31.67
19 1 17 7.8
20 1 16 43.9
21 1 18 23.2
22 1 17 14.0
23 2 17 2.946
24 1 16 32.8
25 1 20 11.5
median 1 18 22GFP; 58%615, 53%618, 57.8%612) and CTL#2 (CAR and mOr-
ange; 54%618 and 52%620). The modified CTL were functional,
and cells transduced with either vector were able to kill the Kappa1
B cell tumor Daudi in Cr51 assay (72%613 and 69%625, respec-
tively) at an R:S of 40:1. We confrmed the function of IL7Ra (#1)
by measuring pSTAT5 and cell proliferation after IL7 administra-
tion (67,64862703 CPM vs 8,7646793 CPM when cells were cul-
tured in media). In addition, we were able to measure IL7 cytokine
from product #2 by ELISA. IL7 production was dependent on the
intensity of antigenic stimulation as demonstrated using different ra-
tios of CTL:EBV-LCLs (4:1, 2:1, 1:1 and 1:2 which induced 3.7, 20,
99, and 192pg/ml IL7, respectively). Finally to demonstrate that
product #1 could sustain #2, we mixed the cultures at a 1:4 ratio.
Over 3 weeks, CTL#1 progressively increased (14% to 87%), while
the frequency of CTL#2 progressively declined over the same period
(63% to 5%).71
HIGH-YIELD OF CD341 CELLS WITH BORTEZOMIB-BASED MOBILIZA-
TION REGIMEN IS ASSOCIATED WITH SPECIFIC GENOMIC EXPRESSION
PATTERNS, DECREASE IN SDF-1 PLASMA LEVELS AND UP-REGULATION
OF CXCR4 IN MULTIPLE MYELOMA (MM) PATIENTS
Ward, M.M.1, Mark, T.1, Manco, M.1, Stern, J.1, O’Loughlin, J.1,
Shore, T.B.1, Pearse, R.N.1, Jayabalan, D.1, Skerrett, D.2, Chen-
King, S.2, Lane, M.E.1, Niesvizky, R.1 1Weill Cornell Medical College,
New York, NY; 2New York, NY
Typical stem cell mobilization regimens in MM include G-CSF
alone or in combination with plerixafor or high-dose cyclophospha-
mide (CTX). Given the known in vitro/in vivo synergy between borte-
zomib (VELCADE, Vel) and alkylating agents, we investigated the
potential for concurrent cytoreduction by adding Vel to the mobiliza-
tion regimen. Eligible patients (pts) had symptomatic, Durie-Salmon
stage II/III MM. All pts received six 21-day cycles of Vel/dexametha-
sone6 liposomal doxorubicin. Cycle 7 only, mobilization (Vel-mob)
comprised Vel 1.3 mg/m2 on days 1, 4, 8, and 11, CTX 3 g/m2 on
day 8, and Filgrastim 10 ug/kg (rhG-CSF) for 10 days from day 9. At
data cut-off, 25pts havebeenmobilized. In comparison topts receiving
just G-CSF alone, there was a significant increase in the median
CD341 collection (22.6106/kgvs10.6106/kg). Inaddition, thenum-
ber of CD341 cells/kg collected far exceeded the study goal of
10X106cells/kg which is typical of using CTX and/or GCSF alone inStem Cells
fused (X106/kg)
Viability
(%)
Day of neutr.
engraftment
Day of plt.
engraftment
5.78 85 14 20
13.22 80 11 13
9.87 60 13 22
9.03 90 10 15
5.44 97 11 21
9.24 94 10 16
17.30 91 10 17
6.32 80 13 24
4.25, 2.74 80, 94 11 18
9.05 93 16 21
no transplant no transplant
12.83 85 11 11
7.38 93 11 11
10.02 92 12 14
12.72 87 13 11
5.31 93 11 13
6.66 92 12 13
9.2 95 11 20
7.40 92 10 11
11.06 98 10 21
no transplant no transplant
3.47 90 16 16
3.96 94 12 12
7.92 93 11 14
5.63 97 10 14
8.48 92 11 15
S180 Oral Presentations23of 25 patients (92%), seeTable 1 for patient data summary. In order
to gain insight into themechanismof this enhancedmobilization, a pi-
lot study investigating gene expression analysis was performed on
CD341 cells purified from frozen control apheresis samples, compar-
ing samples from Vel –mob (n5 7)vs. G-CSF1 CTX(n5 8). A sig-
nificant change in the expression of genes associated with the
following canonical pathways was observed: docosahexaenoic acid sig-
naling, angiopoietin signaling and the molecular mechanisms of can-
cer. In relationship to SDF-1 signaling, there was a 1.44 fold increase
(p# 0.05) inCXCR4mRNA isolated fromCD341 cells in pts treated
with vel-mob when compared to CD341 cells isolated fromGCSF1
CTX treated pts. SDF-1 peripheral blood plasma levels were then
measured in vel-mob treated pts (n 5 7) and compared to the levels
in GCSF alone (n 5 8) treated pts. The mean SDF-1 level in vel-
mob treated pts was significantly decreased (p 5 0.0012) when com-
pared to GCSF alone treated pts (1319 pg/ml vs 2225 pg/ml). Vel-
mob is a novel mobilization regimen that produces very high and pre-
dictable CD341 yields. Vel-mob modulates SDF-1 protein levels in
plasma, CXCR4 gene expression in CD341 cells. We have also iden-
tified important canonical pathways that may be associated with im-
proved mobilization.PEDIATRIC DISORDERS
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PREVENTING REJECTION IN PRIMARY IMMUNODEFICIENCY PATIENTS
WITH DONOR LYMPHOCYTE INFUSIONS
Bittner, T.C.1, Willasch, A.2, Hoenig, M.3, Hauser, M.1, Klein, B.1,
Notheis, G.4, Belohradsky, B.H.4, Renner, E.D.4, Wagner, B.5,
Schulz, A.3, Bader, P.2, Schmid, I.1, Albert, M.H.1 1Dr. von Haunersches
Kinderspital, Munich, Germany; 2University Children’s Hospital, Frank-
furt, Germany; 3University Children’s Hospital, Ulm, Germany; 4Dr.
von Haunersches Kinderspital, Munich, Germany; 5University Hospital
Grosshadern, Munich, Germany
Rationale:The post transplant infusion of donor lymphocytes (DLI)
has been used to increase alloreactivity against residual
host hematopoiesis in malignant diseases after stem cell transplanta-
tion (SCT).DLI can treat impending rejection, prevent relapse in the
face of decreasing donor chimerism or even treat overt relapse in
some forms of leukemia. However the risk of inducing GVHD after
DLI has limited its use after allogeneic SCT for non malignant
disorders such as primary immunodeficiency diseases (PID).
Methods: PID patients with decreasing donor chimerism despite dis-
continuation of immunosuppression were treated with DLI. The ini-
tial dose of CD31 cells per kg body weight was up to 5*105 for
matched sibling donors (MSD), 1*105 for matched unrelated donors
(MUD) and 2.5*104 for haploidentical family donors (MMFD) in
the absence of GVHD. Patients were to receive additional DLI at 4-
6 week intervals in increasing doses until either GVHD or a stabiliza-
tion/reversal of mixed chimerism was observed.
Results: Ten patients (1 XLP, 2 SCID, 7 WAS) experienced de-
creasing donor chimerism at a median of 94 days (range 62-180
days) after myeloablative (n 5 8, non-SCID) or reduced intensity
(n 5 2, SCID) conditioning SCT from MSD (n 5 1), MUD (n 5
7) or MMFD (n 5 2). None of the patients had had pretransplant
maternal engraftment. They received DLI from their original do-
nors at a median of 120 days (78-366) after SCT. At a median follow
up of 779 days (41-3807) after first DLI and amedian of 5DLI (2-14)
we observed a stabilization of mixed chimerism in 5 patients and im-
provement in 5. None experienced complete rejection or returned to
full donor chimerism. Of note, none of the patients experienced
GVHD of any grade.
Conclusion: DLI after SCT for PID is feasible and may be able to
halt impending rejection. This observation may be especially impor-
tant in the light of an increasing use of reduced intensity condition-
ing regimes with presumably a higher incidence of graft failure and
the fact that many PID can be considered cured even with stable,
low level donor chimerism. We propose a graded dosing regimen
of CD31 cells depending on donor/recipient HLA disparity to min-
imize the risk for DLI induced GVHD, which appeared to be safe
and effective in our patients.73
OPTIMIZING THE BUSULFAN DOSING REGIMEN TO GET A MORE PRE-
DICTABLE EXPOSURE: A DATA DRIVEN ANALYSIS
Bartelink, I.H.1, Boelens, J.J.1, Bredius, R.G.M.2, Egberts, A.C.G.1,
Biering, M.1, Shaw, P.3, Nath, C.E.3, Hempel, G.4, Zwaveling, J.2,
Danhof, M.5, Knibbe, C.A.J.5,6 1University Medical Center Utrecht,
Utrecht, Netherlands; 2Leiden University Medical Center, Leiden,
Netherlands; 3The Children’s Hospital at Westmead, Sydney, Australia;
4University of Muenster, Muenster, Germany; 5Leiden/Amsterdam
Center for Drug Research, Leiden University, Leiden, Netherlands; 6St.
Antonius Hospital, Nieuwegein, Nieuwegein, Netherlands
Background: Therapeutic drug monitoring (TDM) guided dosing
of busulfan is associated with higher event free survival rates due
to less graft-failure/relapses and lower toxicity in hematological
stem cell transplantation (HSCT). The observed differences in
plasma exposures of intravenously administered busulfan to children
may be related with age, or diseases like immune deficiencies. The
question is whether a more predictable exposure can be obtained
by individualization of busulfan dosing in pediatric HSCT. This
study aims to predict the growth related developmental changes in
the pharmacokinetics (PK) of busulfan, using an extensive covariate
analysis, in order to design an individualized dosing regimen.
Methods: In this retrospective multicentre study, 245 patients were
included, ranging between 1 month and 26 years of age. All patients
intravenously received busulfan-based conditioning combined with
therapeutic drug monitoring (TDM). Data were gathered from
four pediatric centers. Demographics, diagnosis, concomitant med-
ication, hematological and clinical chemistry parameters were used
as covariates, using linear and allometric correlations. NONMEM
was used for data and covariates analysis.
Results: Bodyweight significantly influenced the PK of busulfan in
a nonlinear relation. The other evaluated covariates did not influence
the pharmacokinetic parameters. An allometric scaling method was
used to estimate the clearance of each individual, resulting in
the function for clearance: 2.94L/h *(BWi/15kg)
exp a. Based on
objective function, diagnostics and root mean square error, the
model with ‘‘exp a’’ as one single exponent was inferior compared
to a bodyweight-dependent exponent, with a function; exp a 5
1.96*BW20.234. This model resulted in a scaling exponent of 1.51
in neonates (BW 3-5 kg) decreasing to 0.65 in young adults (BW
80-109 kg). The volume of distribution was allometrically scaled
with one single exponent of 0.87. Based upon this final model
a new dosing regimen was designed to obtain an AUC of 95 mg*h/
L for myeloablative or 45 mg*h/L for non-myeloablative regimens.
Conclusions: This population PK model for busulfan in patients
ranging between 1 month and 26 years of age, describes the PK pa-
rameters of busulfan using a continuous non-linear function depend-
ing on bodyweight. The model-derived individualized dosing
regimen, which is expected to lead to a more predictable exposure
of busulfan in each child, will be prospectively evaluated.74
LONG TERM ORGAN STABILITY AND OUTCOME IN CHILDREN AND ADO-
LESCENTS WITH SICKLE CELL DISEASE (SCD) FOLLOWING REDUCED
TOXICITY CONDITIONING (RTC) ALLOGENEIC STEM CELL TRANSPLAN-
TATION (SCT)
Bhatia, M.1, Geyer, M.B.1, Baker, C.1, Zuckerman, W.A.1, Duffy, D.1,
Satwani, P.1, George, D.1, Garvin, J.H.1, Harrison, L.1, Baxter-
Lowe, L.A.4, Schwartz, J.2, Cairo, M.S.1,2,3 1Columbia University,
New York, NY; 2Columbia University, New York, NY; 3Columbia Uni-
versity, New York, NY; 4University of California San Francisco, San
Francisco, CA
Myeloablative (MA) SCT is curative of SCD, and children with
stable donor engraftment no longer experience SCD symptoms
(Walters et al, BBMT 2009), but quality of life may be diminished
by MA SCT related organ toxicity. RTC regimens may potentially
enhance preservation of organ function in patients with SCD. Be-
tween 8/27/2004 and 3/2/10, 18 (16M: 2F) patients with symptom-
atic SCD underwent RTC SCT. Conditioning was Busulfan (4mg/
kg  4d # 4 yrs and 12.8mg/kg  4d . 4 yrs), Fludarabine
(30mg/m2  6d), and Alemtuzumab (2mg/m2  1d, 6mg/m2  2d,
and 20mg/m2  2d). Donor sources: 8-6/6 related bone marrow,
2-6/6 related cord blood (CB), 1-6/6 unrelated CB, 4-5/6 unrelated
